Interferon News and Research

RSS

Antiviral agent accelerates virus clearance in cases of COVID-19

A team of researchers from have found an antiviral therapy that seems to be an effective treatment for patients with moderate coronavirus disease 2019 (COVID-19).

15 May 2020

Researchers identify CoV Mac1 proteins as a potential SARS-CoV-2 drug target

A recent study by researchers at the University of Kansas and published on the preprint server bioRxiv* reveals that Mac1 protein implicated in the infection process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a strikingly similar structure and activity in all coronaviruses – suggesting that possible future treatments targeting this protein may exert broad antiviral activity.

13 May 2020

Clinical trial to evaluate two-drug immunotherapy combination in cancer patients with COVID-19

A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.

12 May 2020

Potential for COVID-19 transmission from human eye

A new study published on the preprint server bioRxiv* in May 2020 reports the presence of ACE2 receptors in the eye at high concentrations. These molecules are the entry points for the SARS-CoV-2 virus that is causing the ongoing COVID-19 pandemic.

12 May 2020

Antiviral cocktail may help treat mild COVID-19 patients

The skyrocketing number of cases due to the coronavirus pandemic has taken a massive toll on the health systems in many countries. Since the advent of the coronavirus disease (COVID-19), hundred of research teams are racing to find an effective vaccine and treatment to combat the deadly infection. Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients.

12 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

Researchers discover molecular mechanism that helps HSV1 infect the brain

Herpes simplex virus (HSV1) infections are initiated at mucosal surfaces where the virus infects epithelial cells.

8 May 2020

Pangolins may be the key to new COVID-19 treatments

Researchers at the Medical University of Vienna, Austria, have made an important discovery about the immune response to coronaviruses in pangolins that could point to new approaches for treating human cases of infection.

8 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Patients recently recovered from COVID-19 produce virus-specific antibodies

Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same.

5 May 2020

COVID-19 progression linked to B cell activation

The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.

4 May 2020

UK-based biotechnology firm discovers potential treatments for Covid-19

A UK-based biotechnology firm has announced the discovery of two separate novel treatments for Covid-19 patients before they are put on ventilators. They are now urgently seeking funding of £4m to accelerate safety studies and clinical trials.

30 Apr 2020

SARS-CoV-2 readily infects human intestinal cells in a laboratory model

A new Dutch study available on bioRxiv uses differentiated human small intestinal organoids in vitro to demonstrate that intestinal epithelium supports the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and elicits a strong generic immune response.

27 Apr 2020

Mapping complex peripheral immune response to severe COVID-19

In a recent article publicly available at medRxiv, researchers from Stanford have presented a single-cell atlas of the peripheral immune response to coronavirus disease (COVID-19), highlighting pertinent immunological features associated with the severe forms of the disease.

26 Apr 2020

Research shows how the immune system reacts to hepatitis C viruses

If a virus penetrates a cell, the immune system reacts immediately and produces the signaling protein interferon.

24 Apr 2020

Goblet cells in the human nasal passage may play key role in enabling COVID-19 infections

Two significant international studies involving hundreds of scientists, including a human geneticist at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that specific cells in the human nasal passage shaped like a champagne glass, known as goblet cells, may play a significant role in enabling COVID-19 infections.

24 Apr 2020

Scientists identify cells likely targeted by novel coronavirus

Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

22 Apr 2020